Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Richard J, Wadas"'
Autor:
David T. Huang, Erin K. McCreary, J. Ryan Bariola, Richard J. Wadas, Kevin E. Kip, Oscar C. Marroquin, Stephen Koscumb, Kevin Collins, Judith A. Shovel, Mark Schmidhofer, Mary Kay Wisniewski, Colleen Sullivan, Donald M. Yealy, Meredith Axe, David A. Nace, Ghady Haidar, Tina Khadem, Kelsey Linstrum, Graham M. Snyder, Christopher W. Seymour, Stephanie K. Montgomery, Bryan J. McVerry, Lindsay Berry, Scott Berry, Russell Meyers, Alexandra Weissman, Octavia M. Peck-Palmer, Alan Wells, Robert Bart, Debbie L. Albin, Tami Minnier, Derek C. Angus
Publikováno v:
Trials, Vol 22, Iss 1, Pp 1-3 (2021)
Abstract Objectives The primary objective is to evaluate the comparative effectiveness of COVID-19 specific monoclonal antibodies (mABs) with US Food and Drug Administration (FDA) Emergency Use Authorization (EUA), alongside UPMC Health System effort
Externí odkaz:
https://doaj.org/article/11a244af7e12486d9480802ecb95cd0a
Autor:
Thomas J. Woltemate, Richard J. Wadas, Erin K. McCreary, Ryan Bariola, Tami Minnier, Oscar C. Marroquin, Mark Schmidhofer, Debbie Albin, Derek C. Angus, Donald M. Yealy
Publikováno v:
Journal of the American College of Emergency Physicians Open, Vol 2, Iss 5, Pp n/a-n/a (2021)
Abstract Monoclonal antibody (mAb) therapy can improve coronavirus disease 2019 outcomes when infused early in select patients. We sought to rapidly create and implement a program for emergency department (ED) mAb infusion to aid care. Using multiple
Externí odkaz:
https://doaj.org/article/43da1956cf0c49238dd8c9ae9611ab2b
Autor:
Kevin E. Kip, Erin K. McCreary, Kevin Collins, Tami E. Minnier, Graham M. Snyder, William Garrard, Jeffrey C. McKibben, Donald M. Yealy, Christopher W. Seymour, David T. Huang, J. Ryan Bariola, Mark Schmidhofer, Richard J. Wadas, Derek C. Angus, Paula L. Kip, Oscar C. Marroquin
Publikováno v:
Annals of Internal Medicine. 176:496-504
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ea8d505ac2ebf5f49edbb028552d57a6
https://doi.org/10.7326/m22-1286
https://doi.org/10.7326/m22-1286
Autor:
Erin K, McCreary, Kevin E, Kip, Kevin, Collins, Tami E, Minnier, Graham M, Snyder, Ashley, Steiner, Russell, Meyers, Tina, Borneman, Michelle, Adam, Lauren, Thurau, Donald M, Yealy, David T, Huang, J Ryan, Bariola, Mark, Schmidhofer, Richard J, Wadas, Derek C, Angus, Paula L, Kip, Oscar C, Marroquin
Publikováno v:
Open Forum Infectious Diseases. 9
Background Monoclonal antibody (mAb) treatment is associated with decreased risk of hospitalization and death in high-risk outpatients with mild to moderate coronavirus disease 2019 (COVID-19) caused by early severe acute respiratory syndrome coronav
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4ef9e71898eae8fa560798fb9f5abcc
https://doi.org/10.1093/ofid/ofac517
https://doi.org/10.1093/ofid/ofac517
Autor:
Erin K. McCreary, J. Ryan Bariola, Richard J. Wadas, Judith A. Shovel, Mary Kay Wisniewski, Michelle Adam, Debbie Albin, Tami Minnier, Mark Schmidhofer, Russell Meyers, Oscar C. Marroquin, Kevin Collins, William Garrard, Lindsay R. Berry, Scott Berry, Amy M. Crawford, Anna McGlothlin, Kelsey Linstrum, Anna Nakayama, Stephanie K. Montgomery, Graham M. Snyder, Donald M. Yealy, Derek C. Angus, Paula L. Kip, Christopher W. Seymour, David T. Huang, Kevin E. Kip
Publikováno v:
JAMA network open. 5(4)
Monoclonal antibody (mAb) treatment decreases hospitalization and death in high-risk outpatients with mild to moderate COVID-19; however, only intravenous administration has been evaluated in randomized clinical trials of treatment. Subcutaneous admi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5777f6a40b54f37e8216db7d53d7ae6
https://pubmed.ncbi.nlm.nih.gov/35412625
https://pubmed.ncbi.nlm.nih.gov/35412625
Autor:
Sadudee Peerapornratana, Priyanka Priyanka, Shu Wang, Ali Smith, Kai Singbartl, Paul M. Palevsky, Lakhmir S. Chawla, Donald M. Yealy, Derek C. Angus, John A. Kellum, David T. Huang, Christopher Keener, Nicole Lucko, Francis Pike, Sachin Yende, Amber E. Barnato, Tammy L. Eaton, Elizabeth Gimbel, Kyle Landis, Diana K. Stapleton, Lisa A. Weissfeld, Michael Willochell, Kourtney A. Wofford, Erik Kulstad, Hannah Watts, Arvind Venkatv, Peter C. Hou, Anthony Massaro, Siddharth Parmar, Alexander T. Limkakeng, Kori Brewer, Theodore R. Delbridge, Allison Mainhart, James R. Miner, Todd L. Allen, Colin K. Grissom, Stuart Swadron, Steven A. Conrad, Richard Carlson, Frank LoVecchio, Ednan K. Bajwa, Michael R. Filbin, Blair A. Parry, Timothy J. Ellender, Andrew E. Sama, Jonathan Fine, Soheil Nafeei, Thomas Terndrup, Margaret Wojnar, Ronald G. Pearl, Scott T. Wilber, Richard Sinert, David J. Orban, Jason W. Wilson, Jacob W. Ufberg, Timothy Albertson, Edward A. Panacek, Sohan Parekh, Scott R. Gunn, Jon S. Rittenberger, Richard J. Wadas, Andrew R. Edwards, Matthew Kelly, Henry E. Wang, Talmage M. Holmes, Michael T. McCurdy, Craig Weinert, Estelle S. Harris, Wesley H. Self, Diane Dubinski, Carolyn A. Phillips, Ronald M. Migues
Publikováno v:
Kidney International Reports
Introduction About one-third of critically ill patients with acute kidney injury (AKI) develop persistently decreased kidney function, known as acute kidney disease (AKD), which may progress to chronic kidney disease (CKD). Although sepsis is the mos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1f34acaa7d471a1e54cd55fc3d69864
https://doi.org/10.1016/j.ekir.2020.03.005
https://doi.org/10.1016/j.ekir.2020.03.005
Autor:
Erin K. McCreary, J. Ryan Bariola, Tami E. Minnier, Richard J. Wadas, Judith A. Shovel, Debbie Albin, Oscar C. Marroquin, Kevin E. Kip, Kevin Collins, Mark Schmidhofer, Mary Kay Wisniewski, David A. Nace, Colleen Sullivan, Meredith Axe, Russell Meyers, Alexandra Weissman, William Garrard, Octavia M. Peck-Palmer, Alan Wells, Robert D. Bart, Anne Yang, Lindsay R. Berry, Scott Berry, Amy M. Crawford, Anna McGlothlin, Tina Khadem, Kelsey Linstrum, Stephanie K. Montgomery, Daniel Ricketts, Jason N. Kennedy, Caroline J. Pidro, Ghady Haidar, Graham M. Snyder, Bryan J. McVerry, Donald M. Yealy, Derek C. Angus, Anna Nakayama, Rachel L. Zapf, Paula L. Kip, Christopher W. Seymour, David T. Huang
Publikováno v:
Contemporary clinical trials. 119
Monoclonal antibodies (mAb) that neutralize SARS-CoV-2 decrease hospitalization and death compared to placebo in patients with mild to moderate COVID-19; however, comparative effectiveness is unknown. We report the comparative effectiveness of bamlan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9320c893865a47ef9207e5721f0dc1f4
https://pubmed.ncbi.nlm.nih.gov/35697146
https://pubmed.ncbi.nlm.nih.gov/35697146
Autor:
Richard J. Wadas, Mary Kay Wisniewski, Lindsay R. Berrry, Scott M. Berry, Anna McGlothlin, Anna Nakayama, Christopher W. Seymour, Judith A Shovel, Donald M. Yealy, Mark Schmidhofer, Erin K McCreary, Kevin E. Kip, Tami Minnier, Stephanie K. Montgomery, Derek C. Angus, David T. Huang, Kelsey Linstrum, William Garrard, Paula L Kip, Oscar C. Marroquin, Debbie Albin, Kevin Collins, Michelle Adam, Graham M. Snyder, Russell Meyers, Amy M. Crawford, J Ryan Bariola
ImportanceMonoclonal antibody (mAb) treatment decreases hospitalization and death in outpatients with mild to moderate COVID-19; however, only intravenous administration has been evaluated in randomized clinical trials of treatment. Subcutaneous admi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7d9b8ba79e9a9f2e325d1ad2e5b301ba
https://doi.org/10.1101/2021.11.30.21266756
https://doi.org/10.1101/2021.11.30.21266756
Autor:
Debbie Albin, Ryan Bariola, Oscar C. Marroquin, Thomas J. Woltemate, Tami Minnier, Mark Schmidhofer, Erin K McCreary, Derek C. Angus, Richard J. Wadas, Donald M. Yealy
Publikováno v:
Journal of the American College of Emergency Physicians Open, Vol 2, Iss 5, Pp n/a-n/a (2021)
Monoclonal antibody (mAb) therapy can improve coronavirus disease 2019 outcomes when infused early in select patients. We sought to rapidly create and implement a program for emergency department (ED) mAb infusion to aid care. Using multiple strategi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02eb62470b944d3be4f5315d57addacb
https://doi.org/10.1002/emp2.12550
https://doi.org/10.1002/emp2.12550
Autor:
Scott M. Berry, Tina Khadem PharmD, David A. Nace, Daniel Ricketts Mt, Alexandra Weissman, Kevin E. Kip, Robert Bart, Russell Meyer, Jason N Kennedy Ms, Graham M. Snyder, Stephanie K Montgomery Ms, Meredith Axe Bs, Tami Minnier Ms, Ghady Haidar, William Garrard, J Ryan Bariola, Colleen Sullivan Mha, Bryan J. McVerry, Kelsey Linstrum Ms, Octavia M Peck-Palmer, Alan Wells, Paula L Kip, Lindsay R. Berry, Dave T Huang, Richard J. Wadas, Judith A Shovel, Anne Yang, Kevin Collins, Anna McGlothin, Oscar C. Marroquin, Amy M. Crawford, Caroline J Pidro Bs, Derek C. Angus, Mark Schmidhofer, Erin K McCreary PharmD, Christopher W. Seymour, Mary K Wisniewski Ma, Debbie L Albin Bs
BackgroundNeutralizing monoclonal antibodies (mAb) targeting SARS-CoV-2 decrease hospitalization and death in patients with mild to moderate Covid-19. Yet, their clinical use is limited, and comparative effectiveness is unknown.MethodsWe present the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1d331ec780e2e75f2d615f4d06b82668
https://doi.org/10.1101/2021.09.03.21262551
https://doi.org/10.1101/2021.09.03.21262551